24 Porte du Grand
81 articles with MEDICREA
MEDICREA® Hosts Third Annual User Group Meeting (MAIA) in Lyon, France Followed by Attendance at SRS in Montreal, Canada
The MEDICREA® Group announced that it hosted the third edition of its annual MEDICREA® Artificial Intelligence and Analytics meeting in Lyon, France from September 12-14, and continued their conversations at the 54th annual meeting & course hosted by SRS in Montreal, Canada.
The Medicrea Group reports its unaudited results for the first half of 2019, as approved by the Board of Directors on September 16, 2019.
The MEDICREA® Group announced that it has received FDA-Clearance for TULIP GENESIS™ which completes its UNiD™ ASI platform technology.
The MEDICREA® Group, pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD® ASI proprietary software platform, services and technologies, announced that the United States Patent Office has recently issued the Company additional key patents related to the UNiD ASI proprietary technology platform.
The Medicrea Group, pioneering the transformation of spinal surgery through artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI proprietary software platform, services and technologies, reports its unaudited results for the first quarter of 2019.
Medicrea Hosts Second Annual Meeting Focused on Artificial Intelligence and Analytics in New York, USA
The MEDICREA® Group, pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD ASI™ proprietary software platform, services and technologies, announced that it hosted the second edition of its annual Medicrea Artificial Intelligence and Analytics Meeting in New York, NY, USA from April 26-27.
MEDICREA® Enhances Its Proprietary UNiD ASI™ Service Platform with the Addition of an FDA-Cleared Device Planning and Selection Service
Clearance of its proprietary surgical planning software, UNiD HUB™, to integrate a complete database of the Company’s implant portfolio to directly simulate and select implants during surgical planning provided for surgery, enabling significant improvements in surgical efficiency.
The Medicrea Group announced full year 2018 sales.
Medicrea Announces $30 Million Senior Secured Notes Issue and a Warrants Issue wholly subscribed by Perceptive Advisors
The Medicrea Group today announced the closing of a $30 million senior secured notes issue by Medicrea and wholly subscribed by Perceptive Advisors, a leading multi-strategy healthcare investment firm.
This Press Release includes hyperlinks. Click the blue words to access extra content including videos and abstracts.
The Medicrea Group announced today that the company will host one-on-one investor meetings during the 9th Annual Craig-Hallum Alpha Select Conference at the Sheraton New York Times Square Hotel on Thursday, November 15, 2018.
Third quarter sales: +14% (at constant exchange rate).
Medicrea Announces NASS 2018 Presence And Highlights a Recently Published Study Validating Its Predictive Modelling Approach for AIS Patients
The Medicrea Group announced today that the Company is attending the NASS 2018 meeting taking place in Los Angeles, California, from September 26th to 28th, where UNiD™ LAB biomedical engineers will showcase the most recent developments of the Company’s UNiD™ ASI technology.
Published its unaudited results for the first half of 2018, as approved by the Board of Directors on September 12, 2018.
Trades under symbols MRNTY and MRNTF
The Medicrea® Group announced that the Company has signed a joint-venture agreement with the Spine division of National Surgical Pty Ltd. to introduce the Group’s innovative products and patient-specific technologies in Australia and New Zealand.
MEDICREA INTERNATIONAL announces a capital increase of €3,083,777 with 4 U.S. institutional investors.
Continued growth momentum over first half of 2018
The Medicrea® Group announced that it has obtained the first and only 510(k) clearance from the U.S. Food & Drug Administration (FDA) to market patient-specific spinal cages through the extension of its UNiD™ technology to select from its IB3D™ range of 3D-printed titanium interbody devices.
The Medicrea® Group (Euronext Growth Paris: FR0004178572 - ALMED), pioneering the convergence of healthcare IT and next-generation, outcome-centered spinal device design and manufacturing with UNiD ASI™ (Adaptive Spine Intelligence) technology, announced today that the Company has signed a joint-venture agreement with Motion Medical